Kirabo Tess Ayazika

Kirabo Tess Ayazika

Auto-generated profile, based on publicly available information

Kirabo Tess Ayazika

Affiliation Department of Medical Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMargaret Lubwama
Margaret Lubwama
JOJackson Onyuka
Jackson Onyuka
KAKirabo Tess Ayazika
Kirabo Tess Ayazika
LSLeoson Junior Ssetaba
Leoson Junior Ssetaba
JSJoseph Siboko
Joseph Siboko
Martha MushiMartha Mushi
Martha Mushi
Introduction: Proper measures to combat antimicrobial resistance development and spread in Sub Saharan Africa are very crucial bearing in mind the projected burden of antimicrobial resistance which is expected to be increase by 2050. Training of medical doctor and pharmacy students in antimicrobial stewardship is vital to combat antimicrobial resistance. This study was designed to evaluate the knowledge, attitude, and perception of final year medical and pharmacy students on antimicrobial use and antimicrobial resistance at three universities in Uganda, Kenya, and Tanzania. Methodology: A cross-sectional survey was carried out among final year undergraduate medical and pharmacy students at three universities in East Africa. A Self-administered questionnaire was developed which included dichotomous questions and questions using a 4-point Likert scale. The questions were based on knowledge and attitude about antibiotics, and preparedness to use antibiotics in clinical scenarios. Data were analyzed using STATA version 16 following the objective of the study. Results: Three hundred and twenty-eight final year students participated in the survey from MUK 75, MKU 75 and CUHAS 178. Slightly majority of participants were male 192(58.5%) and their median age was 25 [23 – 27] years. In general, 36.6% (120/328) of students had good overall total knowledge. More students at MUK had good knowledge compared to MKU, and CUHAS (72% vs, 40% vs. 20.2%; p<0.001). The mean scores for overall good total knowledge, general knowledge about antibiotics, knowledge about antibiotic resistance, and knowledge about antibiotic use in clinical scenarios were 58% (CI: 57%– 60%), 95% (CI: 94%– 97%), 54% (CI: 52% - 56%), and 46% (CI:44% - 48%) respectively. More pharmacy students compared to medical students had a good attitude and perception on antibiotic use (79.6% vs. 68.4%; p = 0.026). The students at CUHAS perceived being more prepared to use antibiotic in district hospitals compared to MKU and MUK (75.3% vs. 62.7% vs. 65.3%; p = 0.079). While two hundred and seventy (82.3%) students perceived knowing when to start antimicrobial therapy, 112 (34.2%) did not know how to select the appropriate antibiotic (p<0.0001), 97 (29.6%) did not know the antibiotic dose to give (p<0.0001), and 111 (33.8%) did not know when to switch form an intravenous antibiotic to oral regimen (p<0.0001). Conclusion: Final year students have low scores in knowledge about antimicrobial resistance and antibiotic use in clinical scenarios. This has exposed gaps in practical training of students, while they may feel confident, are not fully prepared to prescribe antibiotics in a hospital setting. A multidisciplinary and practical approach involving medical schools across the East African region should be undertaken to train final year undergraduate students in antimicrobial resistance and antimicrobial stewardship programs. Antimicrobial resistance and antimicrobial stewardship courses should be introduced into the curriculum of final year medicine and pharmacy programs.

20 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JPJJ Patten
JJ Patten
PKPatrick Keiser
Patrick Keiser
DGDeisy Gysi
Deisy Gysi
GMGiulia Menichetti
Giulia Menichetti
HMHiroyuki Mori
Hiroyuki Mori
Robert A DaveyRobert A Davey
Robert A Davey
The SARS-CoV-2 pandemic has caused widespread illness, loss of life, and socioeconomic disruption that is unlikely to resolve until vaccines are widely adopted, and effective therapeutic treatments become established. Here, a well curated and annotated library of 6710 clinical and preclinical molecules, covering diverse chemical scaffolds and known host targets was evaluated for inhibition of SARS-CoV-2 infection in multiple infection models. Multi-concentration, high-content immunocytofluorescence-based screening identified 172 strongly active small molecules, including 52 with submicromolar potencies. The active molecules were extensively triaged by in vitro mechanistic assays, including human primary cell models of infection and the most promising, obatoclax, was tested for in vivo efficacy. Structural and mechanistic classification of compounds revealed known and novel chemotypes and potential host targets involved in each step of the virus replication cycle including BET proteins, microtubule function, mTOR, ER kinases, protein synthesis and ion channel function. In the mouse disease model obatoclax effectively reduced lung virus load by 10-fold. Overall, this work provides an important, publicly accessible, foundation for development of novel treatments for COVID-19, establishes human primary cell-based pharmacological models for evaluation of therapeutics and identifies new insights into SARS-CoV-2 infection mechanisms. Significance A bioinformatically rich library of pharmacologically active small molecules with diverse chemical scaffolds and including known host targets were used to identify hundreds of SARS-CoV-2 replication inhibitors using in vitro, ex vivo, and in vivo models. Extending our previous work, unbiased screening demonstrated a propensity for compounds targeting host proteins that interact with virus proteins. Representatives from multiple chemical classes revealed differences in cell susceptibility, suggesting distinct dependencies on host factors and one, Obatoclax, showed 90% reduction of lung virus loads in the mouse disease model. Our findings and integrated analytical approaches will have important implications for future drug screening and how therapies are developed against SARS-CoV-2 and other viruses.

26 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AAAkinsinde Kehinde Adewale
Akinsinde Kehinde Adewale
DDDiana Dinowitz
Diana Dinowitz
DSDavid A. Sack
David A. Sack
WLWensheng Luo
Wensheng Luo
NMNathaniel Matteson
Nathaniel Matteson
IAIwalokun Bamidele Abiodun
Iwalokun Bamidele Abiodun
Cholera is caused by toxigenic Vibrio cholerae serogroups O1 or O139 and is transmitted through contaminated water or food. Conventional detection methods for V. cholerae in environmental water samples, including membrane filtration and culture, typically require about three days, specialized equipment, and technical expertise. A simple and rapid method for detecting the V. cholerae O1 in water could support outbreak prevention, environmental surveillance, and studies of persistence and transmission. Here, we describe a low-cost, streamlined method for detecting toxigenic V. cholerae O1 in environmental water which can detect V. cholerae O1 within 24 hours. We filter one liter of the water through gauze, incubate the gauze in alkaline peptone water (APW) overnight at 37 C, and test the APW sample with a serogroup O1-specific rapid diagnostic test (RDT). To preserve nucleic acid material from APW broth, we place two drops on each circle of a filter paper (Whatman 903), dry it, and later analyze the DNA using PCR and whole genome sequencing. We evaluated this method using 95 environmental samples collected from 17 sites in Lagos, Nigeria. 54 samples were RDT positive and each of these samples were confirmed by culture and by PCR targeting ompW and ctxA as toxigenic V. cholerae O1. Whole-genome sequencing identified these isolates as belonging to the AFR12 lineage. Among the RDT-negative samples, PCR detected 24 samples positive for ompW but negative for ctxA , consistent with non-toxigenic non-O1 V. cholerae , and 11 of these were further identified as non- toxigenic serogroup O139 by qPCR using a commercial assay (Bioperfectus). The cost for the RDT test was <$2.50 per water sample. This low-cost APW enrichment and RDT-based approach enables identification of environmental water contaminated with toxigenic V. cholerae O1 within 24 hours and enables the collection of samples useful for further bacterial molecular characterization. Author Summary: Standard methods to identify water samples contaminated with V. cholerae serotype O1 are commonly used, but their use for public health practice has been limited due cost, time, and resource requirements. This study describes a convenient, efficient and inexpensive method to detect V. cholerae O1 from environmental water samples and evaluates this method using water samples collected from 17 sites in Lagos, Nigeria during 2025. The method involves filtering one liter of water through a gauze pad, followed by overnight incubation of the gauze in alkaline peptone water (APW) enrichment broth. The APW is then tested for cholera using a rapid diagnostic test (RDT) specific for V. cholerae O1. Among 95 environmental water samples, 54 were positive for V. cholerae O1 using the RDTs. This method provides results within one day at a cost of <$2.50 USD per sample. If there is need for additional studies, RDT positive samples can be sent for culture, and nucleic acid from the APW can be saved by spotting the APW on filter paper. The filter paper can then be stored at room temperature indefinitely. All of the RDT positive samples were confirmed by culture and PCR Among the PCR negative samples, 24 samples were PCR positive for non-O1 V. cholerae, including 11 that were positive for non-toxigenic V. cholerae O139 by qPCR. Whole genome sequencing of the samples found the RDT positive samples to be of the AFR12 lineage, and the DNA contained many genetic markers of antibiotic resistance. Identifying cholera contaminated water quickly provides information to health authorities which can facilitate interventions to reduce transmission and can also provide samples for further epidemiologic and molecular studies.